This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jul 1;3(7):893-894.

doi: 10.1001/jamaoncol.2016.6240.

Less Intense Dosing Schedule for a Bone-Modifying Agent

Monica N Fornier¹

Affiliations

PMID: 28125761
DOI: 10.1001/jamaoncol.2016.6240

Comment

Less Intense Dosing Schedule for a Bone-Modifying Agent

Monica N Fornier. JAMA Oncol. 2017.

. 2017 Jul 1;3(7):893-894.

doi: 10.1001/jamaoncol.2016.6240.

Author

Monica N Fornier¹

Affiliation

¹ Breast Medicine Service, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, New York.

PMID: 28125761
DOI: 10.1001/jamaoncol.2016.6240

No abstract available

PubMed Disclaimer

Comment on

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Hortobagyi GN, et al. JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316. JAMA Oncol. 2017. PMID: 28125763 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information